nodes	percent_of_prediction	percent_of_DWPC	metapath
Nelarabine—Nucleic Acid Synthesis Inhibitors—Capecitabine—esophageal cancer	0.867	1	CiPCiCtD
Nelarabine—ADA—pleura—esophageal cancer	0.0178	0.47	CbGeAlD
Nelarabine—Leukoencephalopathy—Cisplatin—esophageal cancer	0.00383	0.0684	CcSEcCtD
Nelarabine—DCK—Pyrimidine salvage reactions—TYMP—esophageal cancer	0.00311	0.0823	CbGpPWpGaD
Nelarabine—DGUOK—bronchus—esophageal cancer	0.00254	0.0671	CbGeAlD
Nelarabine—DGUOK—smooth muscle tissue—esophageal cancer	0.00248	0.0657	CbGeAlD
Nelarabine—DGUOK—trachea—esophageal cancer	0.00228	0.0603	CbGeAlD
Nelarabine—Leukoencephalopathy—Methotrexate—esophageal cancer	0.0021	0.0375	CcSEcCtD
Nelarabine—Peroneal nerve palsy—Capecitabine—esophageal cancer	0.00197	0.0351	CcSEcCtD
Nelarabine—DGUOK—digestive system—esophageal cancer	0.00196	0.0519	CbGeAlD
Nelarabine—DGUOK—Nucleotide metabolism—TYMP—esophageal cancer	0.00181	0.0477	CbGpPWpGaD
Nelarabine—DGUOK—lung—esophageal cancer	0.00164	0.0433	CbGeAlD
Nelarabine—DCK—Pyrimidine metabolism—TYMP—esophageal cancer	0.00142	0.0375	CbGpPWpGaD
Nelarabine—Motor dysfunction—Methotrexate—esophageal cancer	0.00137	0.0244	CcSEcCtD
Nelarabine—Guillain-Barre syndrome—Methotrexate—esophageal cancer	0.00137	0.0244	CcSEcCtD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—KRT14—esophageal cancer	0.00126	0.0333	CbGpPWpGaD
Nelarabine—Mental retardation—Capecitabine—esophageal cancer	0.00122	0.0218	CcSEcCtD
Nelarabine—Blood calcium decreased—Capecitabine—esophageal cancer	0.00117	0.0209	CcSEcCtD
Nelarabine—ADA—digestive system—esophageal cancer	0.00112	0.0297	CbGeAlD
Nelarabine—DGUOK—lymph node—esophageal cancer	0.00112	0.0296	CbGeAlD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—RUNX1—esophageal cancer	0.00103	0.0272	CbGpPWpGaD
Nelarabine—POLA1—lung—esophageal cancer	0.00101	0.0267	CbGeAlD
Nelarabine—DCK—bronchus—esophageal cancer	0.000965	0.0255	CbGeAlD
Nelarabine—Hemiparesis—Methotrexate—esophageal cancer	0.000947	0.0169	CcSEcCtD
Nelarabine—ADA—lung—esophageal cancer	0.000937	0.0248	CbGeAlD
Nelarabine—Peripheral sensory neuropathy—Capecitabine—esophageal cancer	0.000932	0.0166	CcSEcCtD
Nelarabine—Neurotoxicity—Cisplatin—esophageal cancer	0.000932	0.0166	CcSEcCtD
Nelarabine—Blood albumin decreased—Methotrexate—esophageal cancer	0.000909	0.0162	CcSEcCtD
Nelarabine—DCK—trachea—esophageal cancer	0.000867	0.0229	CbGeAlD
Nelarabine—Sensory disturbance—Capecitabine—esophageal cancer	0.00086	0.0153	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—CA1—esophageal cancer	0.000793	0.021	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—BBC3—esophageal cancer	0.000763	0.0202	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—WWOX—esophageal cancer	0.000762	0.0201	CbGpPWpGaD
Nelarabine—DCK—digestive system—esophageal cancer	0.000746	0.0197	CbGeAlD
Nelarabine—Tumour lysis syndrome—Methotrexate—esophageal cancer	0.000715	0.0127	CcSEcCtD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—SFN—esophageal cancer	0.000702	0.0185	CbGpPWpGaD
Nelarabine—Blood potassium decreased—Capecitabine—esophageal cancer	0.000701	0.0125	CcSEcCtD
Nelarabine—POLA1—lymph node—esophageal cancer	0.000691	0.0183	CbGeAlD
Nelarabine—Neurotoxicity—Capecitabine—esophageal cancer	0.000687	0.0123	CcSEcCtD
Nelarabine—Sinus tachycardia—Capecitabine—esophageal cancer	0.000662	0.0118	CcSEcCtD
Nelarabine—ADA—lymph node—esophageal cancer	0.000641	0.0169	CbGeAlD
Nelarabine—DCK—lung—esophageal cancer	0.000623	0.0165	CbGeAlD
Nelarabine—Febrile neutropenia—Cisplatin—esophageal cancer	0.000601	0.0107	CcSEcCtD
Nelarabine—ADA—Nucleotide metabolism—TYMP—esophageal cancer	0.000599	0.0158	CbGpPWpGaD
Nelarabine—Altered state of consciousness—Capecitabine—esophageal cancer	0.000577	0.0103	CcSEcCtD
Nelarabine—ADA—p73 transcription factor network—BBC3—esophageal cancer	0.000562	0.0149	CbGpPWpGaD
Nelarabine—POLA1—Inhibition of replication initiation of damaged DNA by RB1/E2F1—RB1—esophageal cancer	0.000554	0.0147	CbGpPWpGaD
Nelarabine—DCK—Nucleotide metabolism—TYMP—esophageal cancer	0.000553	0.0146	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—FBXW7—esophageal cancer	0.00054	0.0143	CbGpPWpGaD
Nelarabine—Pneumothorax—Capecitabine—esophageal cancer	0.000536	0.00955	CcSEcCtD
Nelarabine—Neurotoxicity—Methotrexate—esophageal cancer	0.000512	0.00912	CcSEcCtD
Nelarabine—Opportunistic infection—Methotrexate—esophageal cancer	0.000492	0.00878	CcSEcCtD
Nelarabine—Balance disorder—Capecitabine—esophageal cancer	0.000487	0.00869	CcSEcCtD
Nelarabine—ADA—p73 transcription factor network—SFN—esophageal cancer	0.000463	0.0122	CbGpPWpGaD
Nelarabine—Febrile neutropenia—Capecitabine—esophageal cancer	0.000443	0.0079	CcSEcCtD
Nelarabine—Infection—Carboplatin—esophageal cancer	0.000437	0.00779	CcSEcCtD
Nelarabine—DCK—lymph node—esophageal cancer	0.000426	0.0113	CbGeAlD
Nelarabine—Hypomagnesaemia—Capecitabine—esophageal cancer	0.000419	0.00748	CcSEcCtD
Nelarabine—Encephalopathy—Capecitabine—esophageal cancer	0.000415	0.0074	CcSEcCtD
Nelarabine—Aphasia—Capecitabine—esophageal cancer	0.000411	0.00732	CcSEcCtD
Nelarabine—Adenosine monophosphate—PDE4D—esophageal cancer	0.000398	0.414	CrCbGaD
Nelarabine—ADA—Circadian rythm related genes—CRTC1—esophageal cancer	0.000394	0.0104	CbGpPWpGaD
Nelarabine—Hyperuricaemia—Cisplatin—esophageal cancer	0.00039	0.00695	CcSEcCtD
Nelarabine—Neuralgia—Capecitabine—esophageal cancer	0.000384	0.00684	CcSEcCtD
Nelarabine—Dysarthria—Cisplatin—esophageal cancer	0.000382	0.00681	CcSEcCtD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—ABL1—esophageal cancer	0.000382	0.0101	CbGpPWpGaD
Nelarabine—Pain—Carboplatin—esophageal cancer	0.000376	0.0067	CcSEcCtD
Nelarabine—POLA1—E2F transcription factor network—XRCC1—esophageal cancer	0.00037	0.00978	CbGpPWpGaD
Nelarabine—Blood uric acid increased—Cisplatin—esophageal cancer	0.000368	0.00656	CcSEcCtD
Nelarabine—Wheezing—Cisplatin—esophageal cancer	0.000351	0.00626	CcSEcCtD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—BAX—esophageal cancer	0.00035	0.00925	CbGpPWpGaD
Nelarabine—Pleural effusion—Capecitabine—esophageal cancer	0.000348	0.0062	CcSEcCtD
Nelarabine—Body temperature increased—Carboplatin—esophageal cancer	0.000348	0.0062	CcSEcCtD
Nelarabine—Fungal infection—Capecitabine—esophageal cancer	0.000345	0.00615	CcSEcCtD
Nelarabine—Neuropathy—Cisplatin—esophageal cancer	0.000339	0.00605	CcSEcCtD
Nelarabine—POLA1—Telomere Maintenance—HIST1H2BM—esophageal cancer	0.000338	0.00893	CbGpPWpGaD
Nelarabine—Adenosine triphosphate—ABL1—esophageal cancer	0.000333	0.347	CrCbGaD
Nelarabine—Febrile neutropenia—Methotrexate—esophageal cancer	0.00033	0.00588	CcSEcCtD
Nelarabine—Rigors—Capecitabine—esophageal cancer	0.000326	0.00582	CcSEcCtD
Nelarabine—Polyp—Methotrexate—esophageal cancer	0.000326	0.00581	CcSEcCtD
Nelarabine—Petechiae—Capecitabine—esophageal cancer	0.000324	0.00577	CcSEcCtD
Nelarabine—Encephalopathy—Methotrexate—esophageal cancer	0.000309	0.00551	CcSEcCtD
Nelarabine—Aphasia—Methotrexate—esophageal cancer	0.000306	0.00545	CcSEcCtD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—esophageal cancer	0.000305	0.00806	CbGpPWpGaD
Nelarabine—Cyst—Methotrexate—esophageal cancer	0.000297	0.00529	CcSEcCtD
Nelarabine—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.000293	0.00522	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—HMGB1—esophageal cancer	0.000291	0.00769	CbGpPWpGaD
Nelarabine—Hypocalcaemia—Capecitabine—esophageal cancer	0.000291	0.00519	CcSEcCtD
Nelarabine—Burning sensation—Methotrexate—esophageal cancer	0.000286	0.00509	CcSEcCtD
Nelarabine—Paralysis—Methotrexate—esophageal cancer	0.000286	0.00509	CcSEcCtD
Nelarabine—ADA—p73 transcription factor network—ABL1—esophageal cancer	0.000282	0.00745	CbGpPWpGaD
Nelarabine—Blood bilirubin increased—Capecitabine—esophageal cancer	0.000282	0.00502	CcSEcCtD
Nelarabine—Dysarthria—Capecitabine—esophageal cancer	0.000282	0.00502	CcSEcCtD
Nelarabine—POLA1—Chromosome Maintenance—HIST1H2BM—esophageal cancer	0.000282	0.00744	CbGpPWpGaD
Nelarabine—Amnesia—Cisplatin—esophageal cancer	0.000279	0.00498	CcSEcCtD
Nelarabine—Gait disturbance—Capecitabine—esophageal cancer	0.000273	0.00487	CcSEcCtD
Nelarabine—Coordination abnormal—Capecitabine—esophageal cancer	0.000271	0.00484	CcSEcCtD
Nelarabine—DGUOK—Metabolism—BLVRB—esophageal cancer	0.000271	0.00715	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—SLC52A3—esophageal cancer	0.000271	0.00715	CbGpPWpGaD
Nelarabine—Pleural effusion—Methotrexate—esophageal cancer	0.000259	0.00462	CcSEcCtD
Nelarabine—ADA—p73 transcription factor network—BAX—esophageal cancer	0.000258	0.00682	CbGpPWpGaD
Nelarabine—Depressed level of consciousness—Capecitabine—esophageal cancer	0.000257	0.00459	CcSEcCtD
Nelarabine—Fungal infection—Methotrexate—esophageal cancer	0.000257	0.00458	CcSEcCtD
Nelarabine—POLA1—DNA Replication Pre-Initiation—PSME2—esophageal cancer	0.000254	0.00672	CbGpPWpGaD
Nelarabine—POLA1—DNA Replication Pre-Initiation—PSME1—esophageal cancer	0.000254	0.00672	CbGpPWpGaD
Nelarabine—Neuropathy—Capecitabine—esophageal cancer	0.00025	0.00446	CcSEcCtD
Nelarabine—POLA1—E2F mediated regulation of DNA replication—RB1—esophageal cancer	0.000247	0.00652	CbGpPWpGaD
Nelarabine—Blood creatinine increased—Cisplatin—esophageal cancer	0.000246	0.00438	CcSEcCtD
Nelarabine—Dehydration—Cisplatin—esophageal cancer	0.000244	0.00435	CcSEcCtD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—esophageal cancer	0.000242	0.0064	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000241	0.00638	CbGpPWpGaD
Nelarabine—Petechiae—Methotrexate—esophageal cancer	0.000241	0.0043	CcSEcCtD
Nelarabine—Neoplasm—Capecitabine—esophageal cancer	0.000241	0.00429	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—ABL1—esophageal cancer	0.000241	0.00636	CbGpPWpGaD
Nelarabine—Hypokalaemia—Cisplatin—esophageal cancer	0.000239	0.00426	CcSEcCtD
Nelarabine—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000236	0.00421	CcSEcCtD
Nelarabine—Sepsis—Capecitabine—esophageal cancer	0.000231	0.00412	CcSEcCtD
Nelarabine—Mental disability—Capecitabine—esophageal cancer	0.000231	0.00412	CcSEcCtD
Nelarabine—Speech disorder—Methotrexate—esophageal cancer	0.000231	0.00411	CcSEcCtD
Nelarabine—DGUOK—Metabolism—CA1—esophageal cancer	0.00023	0.00608	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—SLC10A2—esophageal cancer	0.00023	0.00608	CbGpPWpGaD
Nelarabine—POLA1—Synthesis of DNA—PSME1—esophageal cancer	0.000222	0.00587	CbGpPWpGaD
Nelarabine—POLA1—Synthesis of DNA—PSME2—esophageal cancer	0.000222	0.00587	CbGpPWpGaD
Nelarabine—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000218	0.00389	CcSEcCtD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN2A—esophageal cancer	0.000217	0.00572	CbGpPWpGaD
Nelarabine—Hyperuricaemia—Methotrexate—esophageal cancer	0.000214	0.00381	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—HMGB1—esophageal cancer	0.000213	0.00563	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—CA2—esophageal cancer	0.000211	0.00556	CbGpPWpGaD
Nelarabine—Dysarthria—Methotrexate—esophageal cancer	0.00021	0.00374	CcSEcCtD
Nelarabine—POLA1—DNA Replication—PSME1—esophageal cancer	0.000208	0.0055	CbGpPWpGaD
Nelarabine—POLA1—DNA Replication—PSME2—esophageal cancer	0.000208	0.0055	CbGpPWpGaD
Nelarabine—Amnesia—Capecitabine—esophageal cancer	0.000206	0.00367	CcSEcCtD
Nelarabine—Blood uric acid increased—Methotrexate—esophageal cancer	0.000202	0.0036	CcSEcCtD
Nelarabine—POLA1—G1/S Transition—PSME1—esophageal cancer	0.000201	0.0053	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—PSME2—esophageal cancer	0.000201	0.0053	CbGpPWpGaD
Nelarabine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000198	0.00353	CcSEcCtD
Nelarabine—Lethargy—Capecitabine—esophageal cancer	0.000197	0.00352	CcSEcCtD
Nelarabine—Stomatitis—Cisplatin—esophageal cancer	0.000197	0.00351	CcSEcCtD
Nelarabine—DGUOK—Metabolism—ADH7—esophageal cancer	0.000196	0.00517	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PLCE1—esophageal cancer	0.000196	0.00517	CbGpPWpGaD
Nelarabine—Pain in extremity—Capecitabine—esophageal cancer	0.000193	0.00345	CcSEcCtD
Nelarabine—Osteoarthritis—Capecitabine—esophageal cancer	0.000193	0.00345	CcSEcCtD
Nelarabine—Depressed level of consciousness—Methotrexate—esophageal cancer	0.000192	0.00341	CcSEcCtD
Nelarabine—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000191	0.00341	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000187	0.00495	CbGpPWpGaD
Nelarabine—POLA1—S Phase—PSME1—esophageal cancer	0.000182	0.00481	CbGpPWpGaD
Nelarabine—POLA1—S Phase—PSME2—esophageal cancer	0.000182	0.00481	CbGpPWpGaD
Nelarabine—Ataxia—Capecitabine—esophageal cancer	0.000182	0.00324	CcSEcCtD
Nelarabine—ADA—p73 transcription factor network—RB1—esophageal cancer	0.000182	0.0048	CbGpPWpGaD
Nelarabine—Coma—Methotrexate—esophageal cancer	0.000181	0.00323	CcSEcCtD
Nelarabine—Blood creatinine increased—Capecitabine—esophageal cancer	0.000181	0.00323	CcSEcCtD
Nelarabine—Dehydration—Capecitabine—esophageal cancer	0.00018	0.00321	CcSEcCtD
Nelarabine—Neoplasm—Methotrexate—esophageal cancer	0.000179	0.0032	CcSEcCtD
Nelarabine—Urinary tract disorder—Cisplatin—esophageal cancer	0.000179	0.0032	CcSEcCtD
Nelarabine—Connective tissue disorder—Cisplatin—esophageal cancer	0.000178	0.00318	CcSEcCtD
Nelarabine—Urethral disorder—Cisplatin—esophageal cancer	0.000178	0.00317	CcSEcCtD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN1A—esophageal cancer	0.000177	0.00468	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—ABL1—esophageal cancer	0.000176	0.00466	CbGpPWpGaD
Nelarabine—Hypokalaemia—Capecitabine—esophageal cancer	0.000176	0.00314	CcSEcCtD
Nelarabine—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000174	0.00311	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—CREBBP—esophageal cancer	0.000174	0.00459	CbGpPWpGaD
Nelarabine—Sepsis—Methotrexate—esophageal cancer	0.000172	0.00307	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—GHRL—esophageal cancer	0.000172	0.00454	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—ADH1B—esophageal cancer	0.000172	0.00454	CbGpPWpGaD
Nelarabine—Muscular weakness—Capecitabine—esophageal cancer	0.000171	0.00304	CcSEcCtD
Nelarabine—Eye disorder—Cisplatin—esophageal cancer	0.00017	0.00302	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—PSME2—esophageal cancer	0.000169	0.00447	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—PSME1—esophageal cancer	0.000169	0.00447	CbGpPWpGaD
Nelarabine—Cardiac disorder—Cisplatin—esophageal cancer	0.000168	0.003	CcSEcCtD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—EP300—esophageal cancer	0.000168	0.00445	CbGpPWpGaD
Nelarabine—Abdominal distension—Capecitabine—esophageal cancer	0.000168	0.003	CcSEcCtD
Nelarabine—Adenosine triphosphate—ABCC2—esophageal cancer	0.000167	0.174	CrCbGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—AJUBA—esophageal cancer	0.000167	0.00441	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—TYMP—esophageal cancer	0.000164	0.00433	CbGpPWpGaD
Nelarabine—Mediastinal disorder—Cisplatin—esophageal cancer	0.000164	0.00292	CcSEcCtD
Nelarabine—DGUOK—Metabolism—CYP26A1—esophageal cancer	0.00016	0.00422	CbGpPWpGaD
Nelarabine—Malnutrition—Cisplatin—esophageal cancer	0.000158	0.00282	CcSEcCtD
Nelarabine—Neutropenia—Capecitabine—esophageal cancer	0.000156	0.00279	CcSEcCtD
Nelarabine—DGUOK—Metabolism—ALOX15—esophageal cancer	0.000155	0.00411	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—RB1—esophageal cancer	0.000155	0.0041	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—CDKN2A—esophageal cancer	0.000152	0.00402	CbGpPWpGaD
Nelarabine—Hyperglycaemia—Capecitabine—esophageal cancer	0.000151	0.00269	CcSEcCtD
Nelarabine—Pneumonia—Capecitabine—esophageal cancer	0.00015	0.00267	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—BCL2—esophageal cancer	0.00015	0.00396	CbGpPWpGaD
Nelarabine—Infestation—Capecitabine—esophageal cancer	0.000149	0.00266	CcSEcCtD
Nelarabine—Infestation NOS—Capecitabine—esophageal cancer	0.000149	0.00266	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—AJUBA—esophageal cancer	0.000149	0.00394	CbGpPWpGaD
Nelarabine—Vision blurred—Cisplatin—esophageal cancer	0.000149	0.00265	CcSEcCtD
Nelarabine—Depression—Capecitabine—esophageal cancer	0.000149	0.00265	CcSEcCtD
Nelarabine—DGUOK—Metabolism—TPI1—esophageal cancer	0.000148	0.00392	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GSTO1—esophageal cancer	0.000148	0.00392	CbGpPWpGaD
Nelarabine—Tremor—Cisplatin—esophageal cancer	0.000148	0.00264	CcSEcCtD
Nelarabine—Lethargy—Methotrexate—esophageal cancer	0.000147	0.00262	CcSEcCtD
Nelarabine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000146	0.0026	CcSEcCtD
Nelarabine—Anaemia—Cisplatin—esophageal cancer	0.000146	0.0026	CcSEcCtD
Nelarabine—Stomatitis—Capecitabine—esophageal cancer	0.000145	0.00259	CcSEcCtD
Nelarabine—Osteoarthritis—Methotrexate—esophageal cancer	0.000144	0.00257	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—PTGS2—esophageal cancer	0.000142	0.00376	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—ALDOB—esophageal cancer	0.000142	0.00376	CbGpPWpGaD
Nelarabine—Leukopenia—Cisplatin—esophageal cancer	0.000141	0.00252	CcSEcCtD
Nelarabine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000141	0.00251	CcSEcCtD
Nelarabine—Epistaxis—Capecitabine—esophageal cancer	0.000141	0.00251	CcSEcCtD
Nelarabine—Convulsion—Cisplatin—esophageal cancer	0.000137	0.00244	CcSEcCtD
Nelarabine—DGUOK—Metabolism—GAPDH—esophageal cancer	0.000137	0.00362	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—CRABP1—esophageal cancer	0.000136	0.00359	CbGpPWpGaD
Nelarabine—Ataxia—Methotrexate—esophageal cancer	0.000135	0.00241	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—MLH3—esophageal cancer	0.000135	0.00356	CbGpPWpGaD
Nelarabine—Myalgia—Cisplatin—esophageal cancer	0.000135	0.0024	CcSEcCtD
Nelarabine—Hypoaesthesia—Capecitabine—esophageal cancer	0.000133	0.00237	CcSEcCtD
Nelarabine—Urinary tract disorder—Capecitabine—esophageal cancer	0.000132	0.00236	CcSEcCtD
Nelarabine—Oedema peripheral—Capecitabine—esophageal cancer	0.000132	0.00235	CcSEcCtD
Nelarabine—Connective tissue disorder—Capecitabine—esophageal cancer	0.000131	0.00234	CcSEcCtD
Nelarabine—POLA1—E2F transcription factor network—CREBBP—esophageal cancer	0.000131	0.00347	CbGpPWpGaD
Nelarabine—Urethral disorder—Capecitabine—esophageal cancer	0.000131	0.00234	CcSEcCtD
Nelarabine—POLA1—E2F transcription factor network—RB1—esophageal cancer	0.000131	0.00346	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—CDKN1A—esophageal cancer	0.000131	0.00345	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GNG7—esophageal cancer	0.000129	0.00341	CbGpPWpGaD
Nelarabine—Oedema—Cisplatin—esophageal cancer	0.000129	0.0023	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—CCND1—esophageal cancer	0.000129	0.0034	CbGpPWpGaD
Nelarabine—Infection—Cisplatin—esophageal cancer	0.000128	0.00228	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000127	0.00337	CbGpPWpGaD
Nelarabine—Nervous system disorder—Cisplatin—esophageal cancer	0.000126	0.00225	CcSEcCtD
Nelarabine—Thrombocytopenia—Cisplatin—esophageal cancer	0.000126	0.00225	CcSEcCtD
Nelarabine—Eye disorder—Capecitabine—esophageal cancer	0.000125	0.00223	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—CDKN1A—esophageal cancer	0.000124	0.00329	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—EP300—esophageal cancer	0.000124	0.00328	CbGpPWpGaD
Nelarabine—Cardiac disorder—Capecitabine—esophageal cancer	0.000124	0.00221	CcSEcCtD
Nelarabine—Anorexia—Cisplatin—esophageal cancer	0.000123	0.00219	CcSEcCtD
Nelarabine—Angiopathy—Capecitabine—esophageal cancer	0.000121	0.00216	CcSEcCtD
Nelarabine—DGUOK—Metabolism—ALDH2—esophageal cancer	0.000121	0.0032	CbGpPWpGaD
Nelarabine—Mediastinal disorder—Capecitabine—esophageal cancer	0.000121	0.00215	CcSEcCtD
Nelarabine—Hypotension—Cisplatin—esophageal cancer	0.000121	0.00215	CcSEcCtD
Nelarabine—Chills—Capecitabine—esophageal cancer	0.00012	0.00214	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—EP300—esophageal cancer	0.000118	0.00313	CbGpPWpGaD
Nelarabine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000117	0.00209	CcSEcCtD
Nelarabine—Mental disorder—Capecitabine—esophageal cancer	0.000117	0.00209	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000117	0.00308	CbGpPWpGaD
Nelarabine—Malnutrition—Capecitabine—esophageal cancer	0.000116	0.00208	CcSEcCtD
Nelarabine—Neutropenia—Methotrexate—esophageal cancer	0.000116	0.00207	CcSEcCtD
Nelarabine—Paraesthesia—Cisplatin—esophageal cancer	0.000116	0.00206	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—esophageal cancer	0.000115	0.00305	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GSTT1—esophageal cancer	0.000115	0.00304	CbGpPWpGaD
Nelarabine—Dyspnoea—Cisplatin—esophageal cancer	0.000115	0.00205	CcSEcCtD
Nelarabine—POLA1—E2F transcription factor network—CDKN2A—esophageal cancer	0.000115	0.00304	CbGpPWpGaD
Nelarabine—Dysgeusia—Capecitabine—esophageal cancer	0.000114	0.00203	CcSEcCtD
Nelarabine—DGUOK—Metabolism—CYP2A6—esophageal cancer	0.000114	0.003	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—RB1—esophageal cancer	0.000114	0.003	CbGpPWpGaD
Nelarabine—Back pain—Capecitabine—esophageal cancer	0.000113	0.00201	CcSEcCtD
Nelarabine—Decreased appetite—Cisplatin—esophageal cancer	0.000112	0.002	CcSEcCtD
Nelarabine—Pneumonia—Methotrexate—esophageal cancer	0.000112	0.00199	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CDKN1A—esophageal cancer	0.000112	0.00295	CbGpPWpGaD
Nelarabine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000111	0.00198	CcSEcCtD
Nelarabine—Infestation—Methotrexate—esophageal cancer	0.000111	0.00198	CcSEcCtD
Nelarabine—Infestation NOS—Methotrexate—esophageal cancer	0.000111	0.00198	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000111	0.00293	CbGpPWpGaD
Nelarabine—Depression—Methotrexate—esophageal cancer	0.000111	0.00197	CcSEcCtD
Nelarabine—Pain—Cisplatin—esophageal cancer	0.00011	0.00197	CcSEcCtD
Nelarabine—Vision blurred—Capecitabine—esophageal cancer	0.00011	0.00196	CcSEcCtD
Nelarabine—Tremor—Capecitabine—esophageal cancer	0.000109	0.00195	CcSEcCtD
Nelarabine—ADA—p73 transcription factor network—MYC—esophageal cancer	0.000108	0.00286	CbGpPWpGaD
Nelarabine—Stomatitis—Methotrexate—esophageal cancer	0.000108	0.00193	CcSEcCtD
Nelarabine—DGUOK—Metabolism—ENO1—esophageal cancer	0.000108	0.00285	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PTGS1—esophageal cancer	0.000108	0.00285	CbGpPWpGaD
Nelarabine—Anaemia—Capecitabine—esophageal cancer	0.000108	0.00192	CcSEcCtD
Nelarabine—POLA1—Mitotic M-M/G1 phases—HIST1H2BM—esophageal cancer	0.000107	0.00282	CbGpPWpGaD
Nelarabine—Feeling abnormal—Cisplatin—esophageal cancer	0.000106	0.00189	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PSME2—esophageal cancer	0.000106	0.00281	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PSME1—esophageal cancer	0.000106	0.00281	CbGpPWpGaD
Nelarabine—POLA1—Synthesis of DNA—RB1—esophageal cancer	0.000105	0.00278	CbGpPWpGaD
Nelarabine—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000105	0.00187	CcSEcCtD
Nelarabine—Epistaxis—Methotrexate—esophageal cancer	0.000105	0.00187	CcSEcCtD
Nelarabine—Leukopenia—Capecitabine—esophageal cancer	0.000104	0.00186	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—MYC—esophageal cancer	0.000103	0.00272	CbGpPWpGaD
Nelarabine—Loss of consciousness—Capecitabine—esophageal cancer	0.000102	0.00183	CcSEcCtD
Nelarabine—Body temperature increased—Cisplatin—esophageal cancer	0.000102	0.00182	CcSEcCtD
Nelarabine—Cough—Capecitabine—esophageal cancer	0.000102	0.00181	CcSEcCtD
Nelarabine—Myalgia—Capecitabine—esophageal cancer	9.92e-05	0.00177	CcSEcCtD
Nelarabine—Chest pain—Capecitabine—esophageal cancer	9.92e-05	0.00177	CcSEcCtD
Nelarabine—Arthralgia—Capecitabine—esophageal cancer	9.92e-05	0.00177	CcSEcCtD
Nelarabine—POLA1—DNA Replication—RB1—esophageal cancer	9.85e-05	0.0026	CbGpPWpGaD
Nelarabine—Urinary tract disorder—Methotrexate—esophageal cancer	9.84e-05	0.00175	CcSEcCtD
Nelarabine—Urethral disorder—Methotrexate—esophageal cancer	9.76e-05	0.00174	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—NOS2—esophageal cancer	9.63e-05	0.00254	CbGpPWpGaD
Nelarabine—Confusional state—Capecitabine—esophageal cancer	9.59e-05	0.00171	CcSEcCtD
Nelarabine—Oedema—Capecitabine—esophageal cancer	9.51e-05	0.00169	CcSEcCtD
Nelarabine—POLA1—G1/S Transition—RB1—esophageal cancer	9.49e-05	0.00251	CbGpPWpGaD
Nelarabine—Infection—Capecitabine—esophageal cancer	9.44e-05	0.00168	CcSEcCtD
Nelarabine—POLA1—Mitotic M-M/G1 phases—MAD2L1—esophageal cancer	9.44e-05	0.00249	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—CDKN1A—esophageal cancer	9.4e-05	0.00248	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	9.4e-05	0.00248	CbGpPWpGaD
Nelarabine—Nervous system disorder—Capecitabine—esophageal cancer	9.32e-05	0.00166	CcSEcCtD
Nelarabine—Eye disorder—Methotrexate—esophageal cancer	9.31e-05	0.00166	CcSEcCtD
Nelarabine—Thrombocytopenia—Capecitabine—esophageal cancer	9.31e-05	0.00166	CcSEcCtD
Nelarabine—Asthenia—Cisplatin—esophageal cancer	9.25e-05	0.00165	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	9.25e-05	0.00244	CbGpPWpGaD
Nelarabine—Cardiac disorder—Methotrexate—esophageal cancer	9.24e-05	0.00165	CcSEcCtD
Nelarabine—DGUOK—Metabolism—CYP1B1—esophageal cancer	9.16e-05	0.00242	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	9.1e-05	0.0024	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	9.1e-05	0.0024	CbGpPWpGaD
Nelarabine—Anorexia—Capecitabine—esophageal cancer	9.06e-05	0.00162	CcSEcCtD
Nelarabine—Angiopathy—Methotrexate—esophageal cancer	9.04e-05	0.00161	CcSEcCtD
Nelarabine—ADA—Metabolism—SLC52A3—esophageal cancer	8.99e-05	0.00237	CbGpPWpGaD
Nelarabine—ADA—Metabolism—BLVRB—esophageal cancer	8.99e-05	0.00237	CbGpPWpGaD
Nelarabine—Mediastinal disorder—Methotrexate—esophageal cancer	8.98e-05	0.0016	CcSEcCtD
Nelarabine—POLA1—E2F transcription factor network—EP300—esophageal cancer	8.94e-05	0.00236	CbGpPWpGaD
Nelarabine—Chills—Methotrexate—esophageal cancer	8.94e-05	0.00159	CcSEcCtD
Nelarabine—Hypotension—Capecitabine—esophageal cancer	8.88e-05	0.00158	CcSEcCtD
Nelarabine—Diarrhoea—Cisplatin—esophageal cancer	8.82e-05	0.00157	CcSEcCtD
Nelarabine—Mental disorder—Methotrexate—esophageal cancer	8.73e-05	0.00156	CcSEcCtD
Nelarabine—Malnutrition—Methotrexate—esophageal cancer	8.67e-05	0.00155	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	8.66e-05	0.00154	CcSEcCtD
Nelarabine—DGUOK—Metabolism—CYP19A1—esophageal cancer	8.62e-05	0.00228	CbGpPWpGaD
Nelarabine—POLA1—S Phase—RB1—esophageal cancer	8.62e-05	0.00228	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	8.61e-05	0.00227	CbGpPWpGaD
Nelarabine—Insomnia—Capecitabine—esophageal cancer	8.6e-05	0.00153	CcSEcCtD
Nelarabine—Paraesthesia—Capecitabine—esophageal cancer	8.54e-05	0.00152	CcSEcCtD
Nelarabine—Dysgeusia—Methotrexate—esophageal cancer	8.49e-05	0.00151	CcSEcCtD
Nelarabine—Dyspnoea—Capecitabine—esophageal cancer	8.48e-05	0.00151	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—esophageal cancer	8.44e-05	0.00223	CbGpPWpGaD
Nelarabine—Back pain—Methotrexate—esophageal cancer	8.39e-05	0.0015	CcSEcCtD
Nelarabine—DCK—Metabolism—BLVRB—esophageal cancer	8.29e-05	0.00219	CbGpPWpGaD
Nelarabine—DCK—Metabolism—SLC52A3—esophageal cancer	8.29e-05	0.00219	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—PSME2—esophageal cancer	8.29e-05	0.00219	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—PSME1—esophageal cancer	8.29e-05	0.00219	CbGpPWpGaD
Nelarabine—Decreased appetite—Capecitabine—esophageal cancer	8.26e-05	0.00147	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Capecitabine—esophageal cancer	8.21e-05	0.00146	CcSEcCtD
Nelarabine—Vomiting—Cisplatin—esophageal cancer	8.2e-05	0.00146	CcSEcCtD
Nelarabine—Fatigue—Capecitabine—esophageal cancer	8.2e-05	0.00146	CcSEcCtD
Nelarabine—Vision blurred—Methotrexate—esophageal cancer	8.17e-05	0.00146	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CDKN1A—esophageal cancer	8.17e-05	0.00216	CbGpPWpGaD
Nelarabine—Constipation—Capecitabine—esophageal cancer	8.13e-05	0.00145	CcSEcCtD
Nelarabine—Pain—Capecitabine—esophageal cancer	8.13e-05	0.00145	CcSEcCtD
Nelarabine—Anaemia—Methotrexate—esophageal cancer	8.01e-05	0.00143	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—RB1—esophageal cancer	8e-05	0.00211	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—HIST1H2BM—esophageal cancer	7.99e-05	0.00211	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—HMOX1—esophageal cancer	7.86e-05	0.00208	CbGpPWpGaD
Nelarabine—Feeling abnormal—Capecitabine—esophageal cancer	7.83e-05	0.0014	CcSEcCtD
Nelarabine—POLA1—E2F transcription factor network—MYC—esophageal cancer	7.79e-05	0.00206	CbGpPWpGaD
Nelarabine—Gastrointestinal pain—Capecitabine—esophageal cancer	7.77e-05	0.00139	CcSEcCtD
Nelarabine—Leukopenia—Methotrexate—esophageal cancer	7.76e-05	0.00138	CcSEcCtD
Nelarabine—Nausea—Cisplatin—esophageal cancer	7.66e-05	0.00137	CcSEcCtD
Nelarabine—ADA—Metabolism—SLC10A2—esophageal cancer	7.64e-05	0.00202	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CA1—esophageal cancer	7.64e-05	0.00202	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	7.6e-05	0.00201	CbGpPWpGaD
Nelarabine—Cough—Methotrexate—esophageal cancer	7.57e-05	0.00135	CcSEcCtD
Nelarabine—POLA1—Synthesis of DNA—CDKN1A—esophageal cancer	7.55e-05	0.00199	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—ABCB1—esophageal cancer	7.55e-05	0.00199	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—BUB1B—esophageal cancer	7.54e-05	0.00199	CbGpPWpGaD
Nelarabine—Abdominal pain—Capecitabine—esophageal cancer	7.52e-05	0.00134	CcSEcCtD
Nelarabine—Body temperature increased—Capecitabine—esophageal cancer	7.52e-05	0.00134	CcSEcCtD
Nelarabine—Convulsion—Methotrexate—esophageal cancer	7.51e-05	0.00134	CcSEcCtD
Nelarabine—Arthralgia—Methotrexate—esophageal cancer	7.38e-05	0.00132	CcSEcCtD
Nelarabine—Chest pain—Methotrexate—esophageal cancer	7.38e-05	0.00132	CcSEcCtD
Nelarabine—Myalgia—Methotrexate—esophageal cancer	7.38e-05	0.00132	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—HIST1H2BM—esophageal cancer	7.14e-05	0.00189	CbGpPWpGaD
Nelarabine—Confusional state—Methotrexate—esophageal cancer	7.14e-05	0.00127	CcSEcCtD
Nelarabine—POLA1—DNA Replication—CDKN1A—esophageal cancer	7.08e-05	0.00187	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—MAD2L1—esophageal cancer	7.06e-05	0.00187	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CA1—esophageal cancer	7.05e-05	0.00186	CbGpPWpGaD
Nelarabine—DCK—Metabolism—SLC10A2—esophageal cancer	7.05e-05	0.00186	CbGpPWpGaD
Nelarabine—Infection—Methotrexate—esophageal cancer	7.03e-05	0.00125	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—esophageal cancer	7.03e-05	0.00186	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CA2—esophageal cancer	6.99e-05	0.00185	CbGpPWpGaD
Nelarabine—Nervous system disorder—Methotrexate—esophageal cancer	6.94e-05	0.00124	CcSEcCtD
Nelarabine—Thrombocytopenia—Methotrexate—esophageal cancer	6.93e-05	0.00124	CcSEcCtD
Nelarabine—Asthenia—Capecitabine—esophageal cancer	6.82e-05	0.00122	CcSEcCtD
Nelarabine—POLA1—G1/S Transition—CDKN1A—esophageal cancer	6.82e-05	0.0018	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	6.77e-05	0.00179	CbGpPWpGaD
Nelarabine—Anorexia—Methotrexate—esophageal cancer	6.75e-05	0.0012	CcSEcCtD
Nelarabine—Hypotension—Methotrexate—esophageal cancer	6.61e-05	0.00118	CcSEcCtD
Nelarabine—Diarrhoea—Capecitabine—esophageal cancer	6.5e-05	0.00116	CcSEcCtD
Nelarabine—ADA—Metabolism—PLCE1—esophageal cancer	6.5e-05	0.00172	CbGpPWpGaD
Nelarabine—ADA—Metabolism—ADH7—esophageal cancer	6.5e-05	0.00172	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CA2—esophageal cancer	6.45e-05	0.0017	CbGpPWpGaD
Nelarabine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	6.45e-05	0.00115	CcSEcCtD
Nelarabine—Insomnia—Methotrexate—esophageal cancer	6.4e-05	0.00114	CcSEcCtD
Nelarabine—POLA1—S Phase—CCND1—esophageal cancer	6.4e-05	0.00169	CbGpPWpGaD
Nelarabine—Paraesthesia—Methotrexate—esophageal cancer	6.35e-05	0.00113	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—MAD2L1—esophageal cancer	6.31e-05	0.00167	CbGpPWpGaD
Nelarabine—Dyspnoea—Methotrexate—esophageal cancer	6.31e-05	0.00112	CcSEcCtD
Nelarabine—Somnolence—Methotrexate—esophageal cancer	6.29e-05	0.00112	CcSEcCtD
Nelarabine—Dizziness—Capecitabine—esophageal cancer	6.29e-05	0.00112	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—PSME2—esophageal cancer	6.2e-05	0.00164	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—PSME1—esophageal cancer	6.2e-05	0.00164	CbGpPWpGaD
Nelarabine—POLA1—S Phase—CDKN1A—esophageal cancer	6.19e-05	0.00164	CbGpPWpGaD
Nelarabine—Adenosine triphosphate—ABCB1—esophageal cancer	6.16e-05	0.0642	CrCbGaD
Nelarabine—Decreased appetite—Methotrexate—esophageal cancer	6.15e-05	0.0011	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Methotrexate—esophageal cancer	6.11e-05	0.00109	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	6.11e-05	0.00161	CbGpPWpGaD
Nelarabine—Fatigue—Methotrexate—esophageal cancer	6.1e-05	0.00109	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	6.08e-05	0.00161	CbGpPWpGaD
Nelarabine—Pain—Methotrexate—esophageal cancer	6.05e-05	0.00108	CcSEcCtD
Nelarabine—Vomiting—Capecitabine—esophageal cancer	6.04e-05	0.00108	CcSEcCtD
Nelarabine—DCK—Metabolism—ADH7—esophageal cancer	6e-05	0.00158	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PLCE1—esophageal cancer	6e-05	0.00158	CbGpPWpGaD
Nelarabine—Headache—Capecitabine—esophageal cancer	5.96e-05	0.00106	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CCND1—esophageal cancer	5.94e-05	0.00157	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—EP300—esophageal cancer	5.89e-05	0.00156	CbGpPWpGaD
Nelarabine—Feeling abnormal—Methotrexate—esophageal cancer	5.83e-05	0.00104	CcSEcCtD
Nelarabine—Gastrointestinal pain—Methotrexate—esophageal cancer	5.79e-05	0.00103	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CDKN1A—esophageal cancer	5.75e-05	0.00152	CbGpPWpGaD
Nelarabine—ADA—Metabolism—ADH1B—esophageal cancer	5.7e-05	0.00151	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—MYC—esophageal cancer	5.65e-05	0.00149	CbGpPWpGaD
Nelarabine—Nausea—Capecitabine—esophageal cancer	5.65e-05	0.00101	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—BUB1B—esophageal cancer	5.64e-05	0.00149	CbGpPWpGaD
Nelarabine—Abdominal pain—Methotrexate—esophageal cancer	5.59e-05	0.000997	CcSEcCtD
Nelarabine—Body temperature increased—Methotrexate—esophageal cancer	5.59e-05	0.000997	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	5.56e-05	0.00147	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—PSME1—esophageal cancer	5.54e-05	0.00146	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—PSME2—esophageal cancer	5.54e-05	0.00146	CbGpPWpGaD
Nelarabine—ADA—Metabolism—TYMP—esophageal cancer	5.44e-05	0.00144	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CYP26A1—esophageal cancer	5.3e-05	0.0014	CbGpPWpGaD
Nelarabine—DCK—Metabolism—ADH1B—esophageal cancer	5.26e-05	0.00139	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	5.24e-05	0.00139	CbGpPWpGaD
Nelarabine—ADA—Metabolism—ALOX15—esophageal cancer	5.16e-05	0.00136	CbGpPWpGaD
Nelarabine—POLA1—S Phase—MYC—esophageal cancer	5.13e-05	0.00136	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	5.09e-05	0.00135	CbGpPWpGaD
Nelarabine—Asthenia—Methotrexate—esophageal cancer	5.08e-05	0.000905	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—BUB1B—esophageal cancer	5.05e-05	0.00133	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—CREBBP—esophageal cancer	5.04e-05	0.00133	CbGpPWpGaD
Nelarabine—DCK—Metabolism—TYMP—esophageal cancer	5.02e-05	0.00133	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	4.98e-05	0.00132	CbGpPWpGaD
Nelarabine—ADA—Metabolism—GSTO1—esophageal cancer	4.92e-05	0.0013	CbGpPWpGaD
Nelarabine—ADA—Metabolism—TPI1—esophageal cancer	4.92e-05	0.0013	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CYP26A1—esophageal cancer	4.89e-05	0.00129	CbGpPWpGaD
Nelarabine—Diarrhoea—Methotrexate—esophageal cancer	4.84e-05	0.000863	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—CHEK2—esophageal cancer	4.8e-05	0.00127	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—MYC—esophageal cancer	4.76e-05	0.00126	CbGpPWpGaD
Nelarabine—DCK—Metabolism—ALOX15—esophageal cancer	4.76e-05	0.00126	CbGpPWpGaD
Nelarabine—ADA—Metabolism—ALDOB—esophageal cancer	4.72e-05	0.00125	CbGpPWpGaD
Nelarabine—Dizziness—Methotrexate—esophageal cancer	4.68e-05	0.000834	CcSEcCtD
Nelarabine—DCK—Metabolism—GSTO1—esophageal cancer	4.54e-05	0.0012	CbGpPWpGaD
Nelarabine—DCK—Metabolism—TPI1—esophageal cancer	4.54e-05	0.0012	CbGpPWpGaD
Nelarabine—ADA—Metabolism—GAPDH—esophageal cancer	4.54e-05	0.0012	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—NOS3—esophageal cancer	4.52e-05	0.00119	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CRABP1—esophageal cancer	4.5e-05	0.00119	CbGpPWpGaD
Nelarabine—Vomiting—Methotrexate—esophageal cancer	4.5e-05	0.000802	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	4.5e-05	0.00119	CbGpPWpGaD
Nelarabine—Headache—Methotrexate—esophageal cancer	4.43e-05	0.00079	CcSEcCtD
Nelarabine—DCK—Metabolism—ALDOB—esophageal cancer	4.36e-05	0.00115	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	4.35e-05	0.00115	CbGpPWpGaD
Nelarabine—ADA—Metabolism—GNG7—esophageal cancer	4.28e-05	0.00113	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—TP53—esophageal cancer	4.21e-05	0.00111	CbGpPWpGaD
Nelarabine—Nausea—Methotrexate—esophageal cancer	4.2e-05	0.000749	CcSEcCtD
Nelarabine—DCK—Metabolism—GAPDH—esophageal cancer	4.19e-05	0.00111	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CRABP1—esophageal cancer	4.16e-05	0.0011	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	4.14e-05	0.00109	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PTGS2—esophageal cancer	4.13e-05	0.00109	CbGpPWpGaD
Nelarabine—ADA—Metabolism—ALDH2—esophageal cancer	4.01e-05	0.00106	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GNG7—esophageal cancer	3.95e-05	0.00104	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—RB1—esophageal cancer	3.92e-05	0.00104	CbGpPWpGaD
Nelarabine—ADA—Metabolism—GSTT1—esophageal cancer	3.82e-05	0.00101	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CYP2A6—esophageal cancer	3.77e-05	0.000997	CbGpPWpGaD
Nelarabine—DCK—Metabolism—ALDH2—esophageal cancer	3.7e-05	0.000979	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	3.61e-05	0.000954	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PTGS1—esophageal cancer	3.58e-05	0.000945	CbGpPWpGaD
Nelarabine—ADA—Metabolism—ENO1—esophageal cancer	3.58e-05	0.000945	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.53e-05	0.000933	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PSME1—esophageal cancer	3.53e-05	0.000932	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PSME2—esophageal cancer	3.53e-05	0.000932	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GSTT1—esophageal cancer	3.52e-05	0.000931	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CYP2A6—esophageal cancer	3.48e-05	0.00092	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—EP300—esophageal cancer	3.43e-05	0.000908	CbGpPWpGaD
Nelarabine—DCK—Metabolism—ENO1—esophageal cancer	3.3e-05	0.000873	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PTGS1—esophageal cancer	3.3e-05	0.000873	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PSME2—esophageal cancer	3.25e-05	0.00086	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PSME1—esophageal cancer	3.25e-05	0.00086	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.06e-05	0.00081	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CYP1B1—esophageal cancer	3.04e-05	0.000804	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.96e-05	0.000783	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—RB1—esophageal cancer	2.93e-05	0.000775	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CYP19A1—esophageal cancer	2.86e-05	0.000756	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CYP1B1—esophageal cancer	2.81e-05	0.000742	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CYP19A1—esophageal cancer	2.64e-05	0.000698	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—RB1—esophageal cancer	2.62e-05	0.000693	CbGpPWpGaD
Nelarabine—ADA—Metabolism—HMOX1—esophageal cancer	2.61e-05	0.00069	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	2.58e-05	0.000681	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PIK3CA—esophageal cancer	2.54e-05	0.000672	CbGpPWpGaD
Nelarabine—ADA—Metabolism—ABCB1—esophageal cancer	2.51e-05	0.000662	CbGpPWpGaD
Nelarabine—DCK—Metabolism—HMOX1—esophageal cancer	2.41e-05	0.000637	CbGpPWpGaD
Nelarabine—DCK—Metabolism—ABCB1—esophageal cancer	2.31e-05	0.000611	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CDKN2A—esophageal cancer	2.31e-05	0.000609	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—CCND1—esophageal cancer	2.18e-05	0.000576	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	2.11e-05	0.000557	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—EP300—esophageal cancer	2.01e-05	0.00053	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CCND1—esophageal cancer	1.95e-05	0.000515	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CDKN1A—esophageal cancer	1.88e-05	0.000498	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—EP300—esophageal cancer	1.79e-05	0.000474	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—MYC—esophageal cancer	1.75e-05	0.000462	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CREBBP—esophageal cancer	1.67e-05	0.000442	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—MYC—esophageal cancer	1.56e-05	0.000413	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CREBBP—esophageal cancer	1.55e-05	0.000408	CbGpPWpGaD
Nelarabine—ADA—Metabolism—NOS3—esophageal cancer	1.5e-05	0.000396	CbGpPWpGaD
Nelarabine—DCK—Metabolism—NOS3—esophageal cancer	1.38e-05	0.000366	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PTGS2—esophageal cancer	1.37e-05	0.000362	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—TP53—esophageal cancer	1.28e-05	0.000339	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PTGS2—esophageal cancer	1.27e-05	0.000334	CbGpPWpGaD
Nelarabine—ADA—Metabolism—EP300—esophageal cancer	1.14e-05	0.000301	CbGpPWpGaD
Nelarabine—DCK—Metabolism—EP300—esophageal cancer	1.05e-05	0.000278	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PIK3CA—esophageal cancer	8.44e-06	0.000223	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PIK3CA—esophageal cancer	7.78e-06	0.000206	CbGpPWpGaD
